# Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

> **NCT04342117** · — · TERMINATED · sponsor: **SecuraBio** · enrollment: 2 (actual)

## Conditions studied

- Lymphoma, Small Lymphocytic
- Lymphoma
- Lymphoma, Non-Hodgkin
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma

## Interventions

- **DRUG:** duvelisib
- **DRUG:** PI3K inhibitor

## Key facts

- **NCT ID:** NCT04342117
- **Lead sponsor:** SecuraBio
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-23
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Strategy Change
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04342117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04342117, "Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04342117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*